

Long Term Side Effects of Cancer Treatment

Dr. Curt Bodkyn



Incidence

- TT – ASR – 84.8 per million (117.8 – 165.9)
- M:F – 1.3:1
- Leukaemia – 23.6 per million
- CNS tumours – 14.4 per million
- Renal – 6.5 per million

	Frequency	Incidence per ICCC-3 Classification(per million)
I. Leukemias	108	23.6
II. Lymphomas	26	5.6
III. CNS neoplasms	66	14.4
IV. Neuroblastoma	22	4.8
V.Retinoblastoma	17	3.7
VI. Renal tumors	30	6.5
VII. Hepatic tumors	8	1.7
VIII. Malignant bone tumors	18	3.9
IX. Soft tissue sarcomas	26	5.7
X. Germ cell tumors	10	2.2
XI. Other malignant epithelial neoplasms	9	2.0
XII. Other and unspecified malignant neoplasms	3	0.7

Outcome

5 Yr SURVIVAL

- Leukaemia – 60.7 %
- ALL - 70.8 %
- ALL (5- 9 yrs)– 82.2%
- Overall – 70%

Longterm#followup#leukaemia#lymph#rhabdomyo
sarcoma#astrocytoma#homa#wilms##medullobl
astoma#gct#pnet#hodgkin#craniopharyngioma
#neuroblastoma#toxicity#renal#cardiac#fertility
#psychosocial#learningdifficulties#rt#surgery#c
hemotherapy#ifosfamide#ccnu#doxorubicin#me
thotrexate#bleomycin#level1#2#3#cyclophosha
mide#dental#growth#puberty#steroids#osteopo
rosis#avn#cisplatin#carboplatin#hearingloss#se
condarymalignancy#feelings#behavior#relapse#



OVERVIEW

- ALL
- BRAIN TUMOURS
- SOLID TUMOURS

ALL

- Schooling and Learning issues
 - MTX / ARAC
 - RT
- Emotional issues
- Cardiac toxicity
 - Puberty
 - Pregnancy

ALL

- ◆ Avascular necrosis of the femoral head
- ◆ Osteoporosis
- ◆ Fertility
 - ◆ Low risk
 - ◆ Testicular RT
- ◆ Risk associated with blood products
 - ◆ Hepatitic C
 - ◆ Rh sensitivity

BRAIN TUMOURS

- Common tumours
 - Astrocytoma – Sx +/- RT
 - Medulloblastoma – Sx / RT / Chemotherapy
- Sx risk – disability
- RT risk - neuroaxis 24-36 Gy / boost 35-45 Gy
- Learning issues
- Growth
- Puberty

BRAIN TUMOURS

- Renal toxicity
- Hearing loss
- Gonadal dysfunction
- Lung dysfunction

SOLID TUMOURS

- Wilm's tumour
 - RT
 - Nephrectomy
 - renal / cardiac
- Neuroblastoma
 - RT / Sx / fertility
- Rhabdomyosarcoma
 - Fertility/renal

